Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

被引：0
|
作者：
Othman, Jad [1 ,2 ,3 ]
Dillon, Richard [1 ,4 ]
机构：
[1] Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England
[2] Royal North Shore Hosp, Dept Haematol, Sydney, Australia
[3] Univ Sydney, Fac Med & Heath, Sydney, Australia
[4] Guys & St Thomas Hosp NHS Trust, Dept Haematol, London, England
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 07期
关键词：
INDUCTION CHEMOTHERAPY; ADULT PATIENTS; SURVIVAL;
D O I：
10.1016/S2352-3026(23)00092-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E478 / E479
页数：2
相关论文
共 50 条
  • [21] NPM1 Mutations Are a Secondary Genetic Event in NPM1-Mutated Acute Myeloid Leukemia
    Patel, Jay L.
    Schumacher, Jonathan
    Szankasi, Philippe
    Frizzell, Kimberly
    Sorrells, Shelly
    Shen, Wei
    Clayton, Adam
    Jattani, Rakhi
    Kelley, Todd W.
    LABORATORY INVESTIGATION, 2017, 97 : 369A - 369A
  • [22] NPM1 Mutations Are a Secondary Genetic Event in NPM1-Mutated Acute Myeloid Leukemia
    Patel, Jay L.
    Schumacher, Jonathan
    Szankasi, Philippe
    Frizzell, Kimberly
    Sorrells, Shelly
    Shen, Wei
    Clayton, Adam
    Jattani, Rakhi
    Kelley, Todd W.
    MODERN PATHOLOGY, 2017, 30 : 369A - 369A
  • [23] NPM1-mutated acute myeloid leukemia: recent developments and open questions
    Patel, Sanjay S.
    PATHOBIOLOGY, 2024, 91 (01) : 18 - 29
  • [24] NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes
    Liu, Yan-Rong
    Zhu, Hong-Hu
    Ruan, Guo-Rui
    Qin, Ya-Zhen
    Shi, Hong-Xia
    Lai, Yue-Yun
    Chang, Yan
    Wang, Ya-Zhe
    Lu, Dan
    Hao, Le
    Li, Jin-Lan
    Li, Ling-Di
    Jiang, Bin
    Huang, Xiao-Jun
    LEUKEMIA RESEARCH, 2013, 37 (07) : 737 - 741
  • [25] Gemtuzumab ozogamicin as pre transplant treatment in acute myeloid leukaemia (AML)
    Pati, Nalini
    Bradstock, Kenneth F.
    Shaw, Peter J.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 500 - 500
  • [26] Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia
    G. D. Bailey
    L. Doolan
    A. Baskar
    L. C. Smith
    C. H. Seedhouse
    Scientific Reports, 10
  • [27] Low doses of gemtuzumab ozogamicin in adults diagnosed with acute myeloid leukaemia
    Pena Domingo, Marta
    Vives Polo, Susana
    Garrido Diaz, Ana
    Coll Jorda, Rosa
    Ribera Santasusana, J. M.
    Ferra Coll, Christelle
    MEDICINA CLINICA, 2020, 157 (07): : 325 - 328
  • [28] Gemtuzumab-ozogamicin in the treatment of acute myeloid leukaemia in a haematology department
    Lehrer, J.
    Mamez, A. -C.
    Baylatry, M.
    Joly, A. -C.
    Fernandez, C.
    Vekhoff, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 586 - 586
  • [29] Preferential transcription of the mutated allele in NPM1 mutated acute myeloid leukaemia
    Bailey, G. D.
    Doolan, L.
    Baskar, A.
    Smith, L. C.
    Seedhouse, C. H.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [30] Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications
    P Sportoletti
    E Varasano
    R Rossi
    A Mupo
    E Tiacci
    G Vassiliou
    M P Martelli
    B Falini
    Leukemia, 2015, 29 : 269 - 278
12345